DaVita Offers Health Economics and Outcomes Research
DaVita Clinical Research (DCR), a provider of clinical research services focused on kidney care as well as a multitude of specialty therapeutic populations, is setting new standards for its Health Economics and Outcomes Research services.
The DCR Health Economics and Outcomes Research team designs and executes studies and economic models and translates the results into tools and products for its customers. By understanding client needs and current trends in the marketplace, DCR has supported access and utilization of multibillion-dollar drug franchises.
DCR’s Health Economics and Outcomes Research services include:
· Strategic consulting
· Economic modeling
· Epidemiology and biostatistics
· Prospective study design, execution, and analysis
· Disease management design, execution, and evaluation
· Psychometric development and validation
· Commercial reimbursement and formulary placement
· Policy analytics and legislative briefings
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
